Pharmaceuticals from diverse therapeutic classes, such as antidepressants, opioids, NSAIDs, anticonvulsants, anesthetics, and other non-narcotic analgesics, are frequently used as the first line of treatment in pain management. Anticonvulsants, also called antiepileptic medicines, were originally created to treat epileptic seizures. Leading Anticonvulsants Market medications like Lyrica (pregabalin) and Neurontin (gabapentin) have been licensed for the treatment of fibromyalgia, migraine, and neuropathic pain, among other conditions. Anticonvulsants are becoming increasingly important in the treatment of a variety of pain conditions as a result of these approvals. The anticonvulsant market as a whole is highly genericized; yet, Lyrica, the only branded pharmaceutical among the currently marketed medications, dominates the market for anticonvulsants for pain management.
Of the major Anticonvulsants Market currently marketed, Lyrica (pregabalin), Neurontin (gabapentin), Topamax (topiramate), Depakote (Divalproex), and Carbatrol/Tegretol (carbamazepine) are indicated for the management of various types of pain. In 2012, Lyrica registered sales of US$ 5,111 Mn, of which 74% constituted revenue from its pain management indication. Since all the other molecules are generic and have negligible contribution in the pain management application, Anticonvulsants Market will be driven and dominated by the sales of the existing blockbuster drug Lyrica, which constituted a 73.4% share of the total market in 2011. The drug was initially set to lose its patent exclusivity in 2015, which would have negatively impacted the market rendering it completely generic. However, Pfizer has obtained market exclusivity for the drug and its use in pain management through 2018 and is therefore expected to maintain its leadership position.
Read More @ https://cmiinfopiece.blogspot.com/2021/12/the-anticonvulsants-market-size-is.html
